Online citations, reference lists, and bibliographies.
← Back to Search

Fibulin-3 As A Blood And Effusion Biomarker For Pleural Mesothelioma.

H. Pass, S. Levin, M. Harbut, J. Melamed, L. Chiriboga, J. Donington, M. Huflejt, M. Carbone, D. Chia, L. Goodglick, G. Goodman, M. Thornquist, G. Liu, M. D. de Perrot, M. Tsao, C. Goparaju
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
BACKGROUND New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity criteria for a robust biomarker. METHODS We measured fibulin-3 levels in plasma (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both. A blinded validation was subsequently performed. Tumor tissue was examined for fibulin-3 by immunohistochemical analysis, and levels of fibulin-3 in plasma and effusions were measured with an enzyme-linked immunosorbent assay. RESULTS Plasma fibulin-3 levels did not vary according to age, sex, duration of asbestos exposure, or degree of radiographic changes and were significantly higher in patients with pleural mesothelioma (105±7 ng per milliliter in the Detroit cohort and 113±8 ng per milliliter in the New York cohort) than in asbestos-exposed persons without mesothelioma (14±1 ng per milliliter and 24±1 ng per milliliter, respectively; P<0.001). Effusion fibulin-3 levels were significantly higher in patients with pleural mesothelioma (694±37 ng per milliliter in the Detroit cohort and 636±92 ng per milliliter in the New York cohort) than in patients with effusions not due to mesothelioma (212±25 and 151±23 ng per milliliter, respectively; P<0.001). Fibulin-3 preferentially stained tumor cells in 26 of 26 samples. In an overall comparison of patients with and those without mesothelioma, the receiver-operating-characteristic curve for plasma fibulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng of fibulin-3 per milliliter. In a comparison of patients with early-stage mesothelioma with asbestos-exposed persons, the sensitivity was 100% and the specificity was 94.1% at a cutoff value of 46.0 ng of fibulin-3 per milliliter. Blinded validation revealed an area under the curve of 0.87 for plasma specimens from 96 asbestos-exposed persons as compared with 48 patients with mesothelioma. CONCLUSIONS Plasma fibulin-3 levels can distinguish healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions. (Funded by the Early Detection Research Network, National Institutes of Health, and others.).
This paper references
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
M. Zweig (1993)
Molecular evolution of the fibulins: implications on the functionality of the elastic fibulins.
F. Segade (2010)
Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression.
C. Roybal (2005)
Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis.
J. Tong (2011)
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo.
A. Albig (2006)
Use of death certificates in epidemiological studies, including occupational hazards: variations in discordance of different asbestos-associated diseases on best evidence ascertainment.
I. Selikoff (1992)
EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment
Yuanjie Hu (2011)
Basic principles of ROC analysis.
C. Metz (1978)
Fibulin‐3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity
Chung-Feng Hwang (2010)
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
J. Hanley (1982)
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis
Shuji Nomoto (2009)
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
N. Hirayama (2011)
Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases.
T. Sasaki (1996)
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation.
E. Kim (2012)
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
JA Hanley (1982)
EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma
H. Seeliger (2009)
Human fibulin-1D: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family.
H. Tran (1997)
Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction.
M. Michaelides (2006)
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker
A. Sadr-Nabavi (2009)
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
Differential expression of fibulin family proteins in the para-cervical weak zone and other areas of human fetal membranes.
R. Moore (2009)
Imaging , Diagnosis , Prognosis EFEMP 1 as a Novel DNA Methylation Marker for Prostate Cancer : Array-Based DNA Methylation and Expression Profiling
Y. Kim (2011)
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
B. Davidson (2010)
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
A. Fiorelli (2011)
EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Y. Kim (2011)
A Comparative Analysis of the Fibulin Protein Family
N. Kobayashi (2007)
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation
Wen Yue (2007)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts.
S. Barnhart (1997)
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
H. Pass (2004)
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
B. Hu (2009)

This paper is referenced by
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
C. Hooper (2015)
In vivo Optical Coherence Tomography Imaging of the Mesothelium Using Developed Window Models
Y. Ahn (2015)
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas
M. Renner (2013)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
A novel age‐related venous amyloidosis derived from EGF‐containing fibulin‐like extracellular matrix protein 1
M. Tasaki (2019)
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
Overexpression of EFEMP1 Correlates with Tumor Progression and Poor Prognosis in Human Ovarian Carcinoma
J. Chen (2013)
Asbestos and the lung in the 21st century: an update
Silvie Prazakova (2014)
Contribución del análisis del líquido pleural al diagnóstico de los derrames pleurales
L. Ferreiro (2015)
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Takayuki Muraoka (2013)
Advances in the management of pleural disease
J. Corcoran (2013)
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
M. Schneider (2016)
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
F. M. Salinas (2015)
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
Hidenori Matsuzaki (2013)
Malignant mesothelioma as a difficult interdisciplinary problem
W. Rokicki (2017)
Malignant Pleural Mesothelioma : Current Perspectives in Early Detection and Diagnosis
Attapon Cheepsattayakorn (2020)
Est-il possible et utile de faire un diagnostic précoce du mésothéliome pleural malin en 2013 ?
Philippe Astoul (2013)
Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
D. Weber (2014)
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
Mesothelioma: Screening in the modern age
Joanna Sesti (2018)
Discovery of new biomarkers for malignant mesothelioma
J. Creaney (2015)
Diagnostic approach to pleural diseases: new tricks for an old trade
F. Maldonado (2017)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.
M. Corradi (2013)
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
Prasugrel versus Clopidogrel for Acute Coronary Syndromes
S. Schultz (2013)
Current best practice in the evaluation and management of malignant pleural effusions
S. Walker (2017)
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.
Rengyi Xu (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar